[Combination chemotherapy of ovarian cancer with cisplatinum, aclarubicin and tegafur].
Two hundred fifty-nine patients with ovarian cancers were treated with the combination of CDDP, aclarubicin and tegafur. Ninety-seven of them had macroscopic diseases during the combination chemotherapy, and the overall anti-tumor response rate (CR + PR) for these patients was 54.6%. It was 60.0% for the 80 cases with epithelial ovarian cancer among them. The median survival time for the antitumor responders was 18 months, against 7 months for the non-responders and 18 months for 103 patients with advanced ovarian cancer (stage III-IV).
Wada
Y
Y
Dept. of Obstetrics and Gynecology, Tohoku Teishin Hospital.
Suzuki
M
M
Shinagawa
S
S
Saito
Y
Y
Nishiya
I
I
Maki
M
M
Yajima
A
A
Hiroi
M
M
Sato
A
A
D015250:Aclarubicin / Q000008:administration & dosage; D000293:Adolescent; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D002945:Cisplatin / Q000008:administration & dosage; D003131:Combined Modality Therapy; D004341:Drug Evaluation; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D007564:Japan; D008875:Middle Aged; D015337:Multicenter Studies as Topic; D010051:Ovarian Neoplasms / Q000188:drug therapy* / Q000401:mortality / Q000601:surgery; D011379:Prognosis; D012074:Remission Induction; D012086:Reoperation; D005641:Tegafur / Q000008:administration & dosage
D005641:Tegafur; D015250:Aclarubicin; D002945:Cisplatin